Everything tagged "diagnostics and research" across the TickerSpark archives.
ICON is a high-quality CRO facing a tough earnings reset, but improving bookings and a 1.51x book-to-bill point to a possible recovery. The stock looks fairly valued for now, with execution and margin recovery the key swing factors.
Revvity is showing a real earnings recovery, led by strong Diagnostics growth and improving Life Sciences momentum. But the stock already reflects much of that progress, with leverage and valuation keeping the rating at Hold.
Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.
Natera posted 39% Q1 revenue growth and continued rapid oncology and women’s health expansion, but losses and a rich valuation keep the stock at Hold. The report sees strong long-term clinical momentum, yet limited margin of safety at the current price.
IDEXX delivered strong Q1 growth on the back of recurring diagnostics, premium instrument placements, and high customer retention. The stock still looks expensive, but the installed-base flywheel and raised 2026 guidance support a Buy.
Waters is leaning into a larger life-science and diagnostics platform after its BD Biosciences and Diagnostic Solutions acquisition. Strong Q1 growth and raised guidance support a Buy, but leverage and a premium valuation keep the setup balanced.
Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.
IQVIA is pairing healthcare data scale with accelerating Commercial Solutions growth and a record R&D backlog. The stock looks attractive for investors who can accept leverage in exchange for durable life sciences exposure.
Thermo Fisher remains a scaled, resilient life sciences compounder with strong cash generation and raised 2026 guidance. The stock looks attractive on quality, but valuation and leverage argue for patience rather than chasing it higher.
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime